Medical Device and Healthcare Industry Trends — 2026-04-26

Editor's Note: As of our latest update (24 hours since April 25, 2026), exclusive domestic announcements in the medical device and healthcare sector are limited. This report compiles verified data from April 23–25 and key ongoing trends. Unverified or date-uncertain information has been excluded.

Top 5 Headlines of the Day

• CMS and FDA propose Medicare coverage fast-track for innovative devices: Two U.S. federal agencies have proposed a joint, faster path to Medicare coverage for products with FDA "Breakthrough Device" designation, promising to reduce entry costs and time for Korean AI and robotic surgery devices in the U.S.
• Lunit’s breast imaging AI deployed in 330+ U.S. sites; 3D update receives FDA clearance: Lunit officially confirms the distribution of INSIGHT MMG and its upgraded 3D image analysis tool across the U.S.
• FDA rejects proposal to relax AI device regulations: The FDA has denied requests for the total deregulation of certain AI devices, reaffirming its commitment to a risk-based oversight framework.
• HitNews reports on calls to separate medical device manufacturing and product approvals: Domestic experts are pushing for a split similar to the biopharmaceutical sector to align with the Special Act effective December 31, 2026.
• DailyPharm analyzes gaps in Korean digital health reimbursement and regulation: Industry experts note that Korea's digital health infrastructure lags significantly behind the U.S. CMS’s Remote Patient Monitoring (RPM) and the UK’s NICE evaluation model.

Major Corporate Developments (4 Cases)

Lunit — U.S. Expansion and New 3D FDA Clearance

• What happened: Lunit announced that its breast cancer AI diagnostic solution is now deployed in over 330 U.S. clinics, and it has secured additional FDA clearance for an upgraded 3D breast image analysis tool.
• Key Figures: Deployed in 330+ sites; new 3D tool FDA clearance secured.
• Implications: This signals that Korean AI medical device companies are moving beyond initial approvals into large-scale, operational distribution. If the CMS/FDA coverage fast-track becomes reality, companies like Lunit already holding FDA approval will likely be the first to benefit.

GI Vita — Digital healthcare startup secures 4.5 billion KRW in Series A

• What happened: Digital healthcare startup GI Vita, focused on pre-diabetic management, successfully closed a 4.5 billion KRW Series A funding round to bridge the gap between offline medical protocols and digital patient data.
• Key Figures: 4.5 billion KRW Series A.
• Implications: Investor interest in chronic disease prevention remains high, though firms may face institutional hurdles due to the lack of local reimbursement schemes.

FDA (Global) — Rejects deregulation, maintains risk-based oversight

• What happened: The FDA decided to maintain its risk-based regulatory framework, rejecting proposals to completely deregulate certain types of AI medical devices.
• Key Figures: Mention of 50 million USD investment in DTx (Digital Therapeutics) by the pharma industry.
• Implications: MedTech firms anticipating deregulation must adjust their strategies. Korean AI firms must adopt a conservative approach to regulatory risks when entering the U.S.

CMS & FDA (Global) — Joint Proposal for Innovative Device Coverage Fast-Track (April 23)

• What happened: The U.S. CMS and FDA proposed a new, rapid pathway for Medicare coverage for "Breakthrough Device" designated products to close the gap between approval and payment.
• Key Figures: Aiming to shorten a process that currently takes years.
• Implications: Korean AI diagnostic firms like Lunit and Vuno could see direct benefits. There is now a stronger incentive for Korean companies to apply for FDA Breakthrough status.

Policy and Regulation (3 Cases)

Discussions on separating manufacturing and product approvals

• Overview: Experts argue that, like the Biopharmaceutical CDMO Special Act (effective Dec 31, 2026), medical devices should split manufacturing licenses from product approvals to boost the ODM/OEM ecosystem.
• Status: Currently in the discussion phase; legislation pending.
• Impact: Could revitalize the outsourced manufacturing ecosystem, though it requires a major overhaul of current MFDS regulations.

Korea's digital health infrastructure lags behind global standards

• Overview: Unlike the U.S. (CMS's RPM reimbursement) or the UK (NICE’s clinical/cost-effectiveness evaluation), Korea lacks the infrastructure to integrate digital health, DTx, and AI diagnostics into public systems.
• Impact: Without reimbursement, commercialization remains difficult, regardless of technical approval.

MFDS proposal on medical device change management (March 2026)

• Overview: The MFDS proposed a risk-based classification system for product changes (pre-approval, notification, or internal management) to allow for more flexible design updates.
• Impact: Likely to speed up product improvements, though companies must strengthen internal regulatory expertise to avoid compliance risks.

Digital Health & AI Trends

• Lunit INSIGHT MMG 3D update: Now deployed in 330+ U.S. sites with new FDA clearance.
• GI Vita Diabetes Platform: Leveraging 4.5 billion KRW to scale chronic disease prevention and data connectivity.
• FDA AI/Wearable Oversight: While low-risk AI/wearables have seen relaxed guidance, the FDA maintains strict, risk-based oversight for high-risk CDS (Clinical Decision Support) software.

Global MedTech Context

• CMS/FDA fast-track (2026-04-23): Korean AI firms holding or pursuing Breakthrough status stand to benefit from faster path to revenue.
• FDA rejects deregulation (2026-04-09): Firms should stick to traditional 510(k) or PMA paths rather than banking on deregulation.
• FDA low-risk guidance: Opens doors for consumer electronics companies like Samsung and LG to launch health features without full medical device approval.

Investment and M&A

• GI Vita Series A: 4.5 billion KRW for platform expansion.
• Pharma DTx investment: Global pharmaceutical companies have invested approximately 50 million USD into the digital therapeutics space, signaling potential partnership opportunities for Korean firms.

Today's Insight

The CMS/FDA coverage fast-track is a game-changer for Korean AI diagnostic firms, offering a solution to the "post-approval monetization" bottleneck. As Lunit demonstrates with its 330+ U.S. deployments, those already holding FDA clearance are poised to be the first beneficiaries. Domestically, however, the lack of digital health reimbursement forces Korean firms to prioritize international markets—a "Global First, Korea Later" strategy. Regulatory flexibility from the MFDS will be crucial to fostering a more competitive domestic manufacturing base in the long run.

This Week's Checkpoints

• Monitor public comments on the CMS/FDA fast-track proposal and reactions from Lunit/Vuno.
• Track the MFDS notice regarding the implementation of the new medical device change management regulations.
• Watch for discussions on linking medical device legislation to the upcoming Biopharmaceutical CDMO Special Act.

Reader Action Items

• AI Medical Device Professionals: Review FDA "Breakthrough Device" requirements and evaluate your product against the upcoming CMS fast-track criteria.
• Digital Health Investors: Consider the potential of diabetes/chronic disease platforms like GI Vita, but weigh the risk of the absence of local Korean reimbursement.
• Regulatory Affairs Officers: Review the new MFDS change management draft and perform a self-audit on current product change classifications.